Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
17,574,000 | 17,064,000 | 16,485,000 | 16,159,000 | 16,255,000 |
Cost of Goods Sold (COGS) incl. D&A |
5,958,000 | 5,578,000 | 5,130,000 | 4,894,000 | 5,338,000 |
COGS excluding D&A |
4,922,000 | 4,573,000 | 4,278,000 | 4,121,000 | 4,495,000 |
Depreciation & Amortization Expense |
1,036,000 | 1,005,000 | 852,000 | 773,000 | 843,000 |
Gross Income |
11,616,000 | 11,486,000 | 11,355,000 | 11,265,000 | 10,917,000 |
SG&A Expense |
7,955,000 | 7,873,000 | 7,171,000 | 6,662,000 | 7,591,000 |
Research & Development |
2,294,000 | 2,645,000 | 2,206,000 | 1,647,000 | 2,133,000 |
Other SG&A |
5,661,000 | 5,228,000 | 4,965,000 | 5,015,000 | 5,458,000 |
Other Operating Expense |
0 | 0 | 0 | 0 | 21,000 |
Unusual Expense |
165,000 | -64,000 | 9,000 | 52,000 | 210,000 |
Non Operating Income/Expense |
-312,000 | 36,000 | -2,017,000 | 621,000 | -2,615,000 |
Equity in Affiliates (Pretax) |
NA | NA | NA | 0 | 0 |
Interest Expense |
102,000 | 133,000 | 137,000 | 144,000 | 162,000 |
Gross Interest Expense |
102,000 | 133,000 | 137,000 | 144,000 | 162,000 |
Pretax Income |
3,100,000 | 3,595,000 | 2,035,000 | 5,045,000 | 318,000 |
Income Tax |
533,000 | 966,000 | 627,000 | 1,135,000 | 100,000 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
2,567,000 | 2,629,000 | 1,408,000 | 3,910,000 | 218,000 |
Minority Interest Expense |
0 | -339,000 | 0 | 0 | 0 |
Net Income |
2,567,000 | 2,968,000 | 1,408,000 | 3,910,000 | 218,000 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | NA | 0 |
Net Income After Extraordinaries |
2,567,000 | 2,968,000 | 1,408,000 | 3,910,000 | 218,000 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
2,567,000 | 2,968,000 | 1,408,000 | 3,910,000 | 218,000 |
Operational EPS |
0.95 | 1.04 | 0.51 | 1.42 | 0.13 |
EPS (basic) |
0.93 | 1.08 | 0.51 | 1.43 | 0.08 |
EBITDA |
4,697,000 | 4,618,000 | 5,036,000 | 5,376,000 | 4,148,000 |
Depreciation & Amortization Expense |
1,036,000 | 1,005,000 | 852,000 | 773,000 | 843,000 |
Common Shares Outstanding |
NA | 2,818,100 | 2,798,200 | 2,774,900 | 2,775,300 |
Basic Shares Outstanding |
2,760,215 | 2,757,400 | 2,747,400 | 2,736,900 | 2,736,000 |
Diluted Shares Outstanding |
2,820,879 | 2,818,100 | 2,798,200 | 2,774,900 | 2,775,300 |
Diluted EPS after Extraordinary Items |
0.91 | 1.05 | 0.50 | 1.41 | 0.08 |
Discont. Operations Per Share |
NA | 0 | 0 | 0 | 0 |
Continued operations EPS |
NA | 1.08 | 0.51 | 1.43 | 0.08 |
*Figures in thousands of U.S. Dollars except shares outstanding.
